Science 37 Decentralized Clinical Trial

by Science 37  · Based in United States → — One Site. Any Patient. Total Access.
Family Medicine Internal Medicine Oncology
Website Demo Contact
Claim this tool
Is this the maker? Claim the company →

Regulatory Status Disclosed

Overview

Science 37 offers a leading platform for decentralized clinical trials (DCTs), enabling physicians to participate in research remotely and manage patient data efficiently. This approach significantly expands patient access to clinical studies, regardless of their geographical location or proximity to traditional research sites. The platform is designed to bring clinical research directly to patients’ homes, ensuring high-quality care and detailed data collection comparable to conventional site-based trials.

A core component of Science 37’s offering is its FDA-inspected Direct-to-Patient Site, which has demonstrated performance outperforming industry benchmarks in clinical trial enrollment and execution. This unique model allows physicians to engage a broader patient population, accelerating randomization and reducing the burden often associated with traditional site recruitment. The company emphasizes a quality-focused approach, ensuring that all aspects of the decentralized trial process meet rigorous standards.

Science 37 also provides robust patient recruitment services, delivering medical record-qualified, site-ready referrals. This streamlines the enrollment process for physicians and research teams. Furthermore, the platform is supported by a team of over 150 research-grade nurses, who are trained and certified by investigators to deliver exceptional clinical assessments and procedures directly to patients, enhancing the overall quality and reliability of trial data.

Founded by investigators with a vision to make clinical research accessible to anyone, anywhere, anytime, Science 37 continues to innovate in the DCT space. Their solutions are customized to help patients discover, qualify for, and participate in studies, breaking down traditional barriers to research participation. This empowers physicians to contribute to groundbreaking medical advancements while offering their patients novel treatment opportunities.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Direct-to-Patient Site (FDA-inspected)
  • Decentralized Clinical Trial platform
  • Research-grade nursing staff
  • Patient recruitment services
  • Remote patient data management
  • Customized trial solutions
  • Expanded patient access
  • Investigator-trained staff

Use Cases

  • Conducting decentralized clinical trials
  • Expanding patient access to research studies
  • Remote patient monitoring and data collection
  • Streamlining patient recruitment for trials
  • Managing clinical trial operations remotely
  • Facilitating physician participation in research from any location

What Physicians Need to Know

Clinical Trial Matching
Science 37 excels in patient recruitment and enrollment for decentralized clinical trials, leveraging a proprietary Virtual Site and Patient Recruitment solution to identify, medically qualify, and enroll patients without geographic restrictions. They have a proven track record of accelerating enrollment, often significantly faster than traditional sites, and increasing patient diversity. Their approach includes omni-channel outreach, heatmapping technology to pinpoint patients and physicians, and clinician-reviewed eligibility to ensure high-quality, trial-ready referrals. They also offer a dual enrollment pathway, allowing pre-screened patients to choose between participating at a traditional site or from home.
Real-World Evidence Analysis
Science 37's Metasiteu2122 model addresses real-world evidence concerns by enabling study participation regardless of patient location, improving oversight and compliance for observational studies. They collect patient-reported data directly through their app, and telemedicine investigators and mobile nurses input medical data from home visits. Science 37 also focuses on generating real-world representation in clinical trials.
Genomic Data Integration
Science 37 collaborates with Foundation Medicine to integrate deep genomic insights into decentralized oncology clinical research. This partnership uses Foundation Medicine's FoundationSmartTrialsu2122 to identify eligible patients based on comprehensive genomic profiling test results, expanding access to precision cancer care.
Safety Signal Detection
While Science 37's primary focus is on decentralized trial execution, the platform's ability to collect real-time data and monitor patient behavior, including dosing adherence and digital biomarkers (through partnerships like AiCure), can contribute to a more comprehensive safety surveillance system. The integration of electronic health records (EHR) also streamlines information sharing, which is crucial for safety monitoring. Modern safety platforms are increasingly using AI to screen large volumes of structured and unstructured data to flag patterns of interest for signal detection.
Collaboration Features
Science 37's platform is designed to orchestrate decentralized studies, supporting collaboration among telemedicine investigators, mobile nurses, remote coordinators, and patient communities. They partner with CROs, biotechs, pharma, and advocacy groups to optimize recruitment, enrollment, and patient retention. Their collaborations, such as with PPD and Catalent, extend their reach and enable the deployment of decentralized trial technology and services.
Publication Support
Science 37 publishes analyses and white papers on decentralized trials, virtual site strategies, and industry trends, often in collaboration with institutions like the Tufts Center for the Study of Drug Development. These publications cover topics such as the performance of direct-to-patient sites, accelerating research, and achieving diversity in clinical trials.
Physician Tip

For physicians, Science 37's platform offers a way to expand access to clinical trials for your patients, particularly those who face geographic or logistical barriers to traditional site-based participation. The decentralized model, supported by telemedicine investigators and research-grade nurses, allows patients to participate from home while maintaining rigorous oversight and data quality. The integration of EHRs can streamline the sharing of patient health information, reducing administrative burden. Consider referring patients who may benefit from a more flexible trial experience, especially in therapeutic areas where Science 37 has demonstrated strong enrollment, such as CNS, oncology, rare diseases, and infectious diseases.

Science 37's platform integrates with various technologies and services to enable decentralized clinical trials. Key integrations include electronic health records (EHR) for seamless patient data sharing, and partnerships with AI and advanced data analytics companies like AiCure for remote dosing adherence monitoring and digital biomarker measurement. They also collaborate with genomic profiling providers like Foundation Medicine for patient identification in oncology trials and logistics partners like Catalent for direct-to-patient investigational medicinal product delivery. The platform supports eConsent, eSource, ePRO, and telemedicine capabilities.

Details

Category Drug Discovery & Research, Patient Engagement & Education, Telehealth & Virtual Care
Pricing Unknown
  • Science 37 has updated its pricing model to be more performance-based, aligning with industry standards
DeploymentCloud-based platform, mobile app (iOS and Android).
Mobile App1
LanguagesMore than 45 languages.
TrainingUnknown
Target SizeLarge pharmaceutical companies, biotechnology, and CROs.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Science 37's Direct-to-Patient Site is FDA-inspected and has successfully completed multiple FDA inspections, resulting in No Action Indicated (NAI) classifications with zero Form 483 observations. Data generated through their approach has supported various regulatory submissions and approvals. The FDA released its final guidance on Decentralized Clinical Trials in September 2024, acknowledging the importance of DCT elements.
GDPRUnknown AI-estimated
Integrations
EHR Not specified
Specialties Family Medicine, Internal Medicine, Oncology

Social Proof

Customersunknown
Notable
unknown

Support & Reliability

Training ProvidedUnknown

What the Web Says

Science 37 offers a decentralized clinical trial (DCT) platform that aims to make clinical research more accessible and patient-centric. Their model leverages technology, mobile nurses, and telemedicine to allow patients to participate in trials from home, reducing geographical barriers and improving convenience. The company emphasizes its ability to increase patient participation, enhance the patient experience, and collect real-time data.

Overall: Mixed

Strengths

  • Increased patient participation and diverse representation due to reduced geographic barriers and travel burden.
  • Enhanced patient experience and retention rates by offering convenience and flexibility through at-home participation.
  • Faster startup times and accelerated enrollment compared to traditional site-based models.
  • Real-time data collection through technology-enabled solutions.
  • Successfully completed multiple FDA inspections with no significant findings, supporting regulatory submissions and approvals.
  • Offers a comprehensive, fully-integrated, decentralized clinical trial platform with an in-house network of telemedicine investigators and home-health nurses.

Limitations

  • Concerns about job security and multiple rounds of layoffs reported by employees.
  • Potential for technical issues with the patient app, including crashing and data entry problems.
  • Some opinions suggest the company has a history of underdelivering to sponsors, high turnover, and poor management.
  • Science 37's financial performance has fallen short of projections, leading to a significant decrease in valuation and going private.
  • The decentralized trial model may not be suitable for all types of clinical trials.
  • Delays in retrieving patient records have slowed enrollment cycles in the past, though this has reportedly improved with outsourcing.

Based on reviews from: Science 37, Mahalo Health, Reddit, Fierce Biotech, Indeed.com, PreDoc.ai, Applied Clinical Trials Online

Last updated: 2026-09-11

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Science 37 Decentralized Clinical Trial

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Science 37 / PR Newswire
Science 37u00ae and Medgate Partner to Further Globalize Decentralized Clinical Trials
Science 37 announced a strategic partnership with Medgate, a digital health and telemedicine company, to expand its decentralized clinical trial operating system globally. This collaboration aims to enable more provider and patient participation in research across Europe, Asia-Pacific, and the Middle East.
2021-03
PR Newswire
Science 37u00ae and Xperiomeu2122 Partner to Increase the Efficiency and Speed of Rare Disease Studies for Patients and Providers
Science 37 partnered with Xperiome, a global rare disease healthtech company, to enhance the efficiency and speed of rare disease studies. This collaboration leverages Science 37's decentralized clinical trial model to offer more study opportunities with less burden for rare disease patients.
2021-03
Channelchek
Science 37 to be Acquired by eMed in Deal to Expand Virtual Clinical Trials
Clinical research company Science 37 announced its acquisition by telehealth provider eMed in a deal valued at approximately $38 million. This acquisition will allow eMed to utilize Science 37's remote clinical trial capabilities and Metasite technology to expand patient access and accelerate enrollment in clinical studies.
2024-01
Mahalo Health
36 Top Decentralized Clinical Trial Companies
Science 37 is highlighted as a pioneering decentralized clinical trial software company, revolutionizing clinical research with its platform. The article emphasizes Science 37's role in centralizing data collection, ensuring compliance and data security, and providing advanced analytics for efficient trials.
2024-01
Nanalyze
Science 37 Stock for Decentralized Clinical Trials
This article discusses the advantages of Science 37's decentralized clinical trials, citing a case study where Science 37 significantly outpaced a traditional CRO in patient enrollment. It also highlights the company's claim of conducting nearly 100 decentralized clinical trials and engaging over 360,000 patients.
2021-06
Applied Clinical Trials
UCB, Science 37 Partner to Conduct At-Home Trials in Neurology ...
UCB and Science 37 partnered to conduct at-home trials in neurology, leveraging Science 37's decentralized clinical trial model. This collaboration aims to utilize mobile health technologies to bring clinical research directly to patients.
2018-05
SEC.gov
Registration Statement (S-4) - LifeSci Acquisition Corp.
This SEC filing details the business combination between LifeSci Acquisition Corp. and Science 37, highlighting Science 37's proprietary Decentralized Clinical Trial Operating System (DCT OS). The document emphasizes Science 37's patient-centric model, which combines its technology platform with specialized network capabilities for end-to-end trial execution.
unknown
SEC.gov
Prospectus - Science 37 Holdings, Inc.
This prospectus from Science 37 Holdings, Inc. (formerly LifeSci Acquisition Corp.) outlines the company's structure after the business combination. It mentions the issuance of shares to former Science 37 securityholders and discusses the company's focus on its Decentralized Clinical Trial Operating System.
unknown

Videos

Product demos, reviews, and walkthroughs for Science 37 Decentralized Clinical Trial.

View all on YouTube

Frequently Asked Questions

Science 37's DCT model aims to broaden patient access by removing geographical barriers, potentially accelerating recruitment for your drug discovery research. By allowing patients to participate from home, it can also improve retention rates due to increased convenience and reduced burden on participants.
Science 37 leverages a proprietary platform that integrates telemedicine, remote monitoring devices, and eConsent to ensure data integrity and patient compliance. This technology facilitates secure data capture, real-time monitoring of patient activities, and direct communication between patients and the research team.
Regulatory bodies like the FDA and EMA have issued guidance supporting DCTs, recognizing their potential benefits while emphasizing the need for robust data integrity and patient safety measures. Science 37's platform and processes are designed to align with these regulatory requirements, offering comprehensive audit trails and adherence to GxP standards for your IND studies.
While initial setup costs for a DCT might be comparable or slightly higher due to technology integration, the Science 37 model can potentially reduce overall trial costs by minimizing site overhead, travel expenses for patients, and accelerating recruitment timelines. The exact cost implications will depend on the study design and therapeutic area.
Fully decentralized trials may have limitations for studies requiring complex procedures, frequent in-person assessments, or specific patient populations with limited digital literacy or access. A hybrid model, combining decentralized elements with some site visits, or a traditional trial might be more appropriate in such cases, depending on the drug discovery phase and the specific needs of the patient population.
Science 37 employs a multi-faceted approach to ensure data quality and reliability, including validated remote monitoring devices, direct data capture from patients, and centralized review by clinical teams. They also have established protocols for real-time adverse event reporting and remote source data verification to maintain data integrity and patient safety.
Several other companies offer decentralized or hybrid clinical trial solutions, each with varying platforms and service models. Science 37 differentiates itself through its proprietary, integrated technology platform, extensive experience in executing fully decentralized trials across various therapeutic areas, and a dedicated network of investigators and research coordinators.

Related Tools

Noodle Biomedical Literature Discovery
Helena Bioinformatics
Drug Discovery & Research
Noodle is a biomedical literature discovery platform that allows researchers to search publications by meaning, inspect paper details, and explore related evidence through citation connections and semantic neighborhoods. It offers a public read-only Model Context Protocol (MCP) interface for AI agents.
Free
Trially AI
Trially AI
Drug Discovery & Research
Trially's HIPAA-compliant AI platform matches, engages, and enrolls patients into trials with high accuracy, built for physicians and research sites.
Trial Library
Trial Library
Drug Discovery & Research
Trial Library's AI-native platform is embedded in community oncology practices to identify eligible patients for oncology clinical trials. It integrates clinical trials into routine care, activating providers, identifying eligible patients, and navigating them through the trial lifecycle across health systems, biopharma, and payers.
Mendel.ai
Mendel.ai
Clinical Decision Support & Reference
Mendel.ai uses Neuro-Symbolic AI to sort patient cohorts from EHRs for clinical trial matching, accelerating research.
Contact for pricing
Haystack Enroll
Haystack Health
Drug Discovery & Research
Haystack Health is a clinical trial platform that utilizes AI and care navigation to connect health plan members and ACO patients with relevant clinical trials, aiming to expand treatment access and improve outcomes.
Custom quote
Dyania Health Clinical Trial Recruitment
Dyania Health
Drug Discovery & Research
Dyania Health's AI-powered software automates patient identification from EHRs for clinical trial recruitment, serving hospitals, health systems, and pharmaceutical companies.

See all Drug Discovery & Research tools →

Suggest an Edit → | Last Verified: 2026-06-11 | First Added: 2026-06-11

Investors who backed Science 37 Decentralized Clinical Trial

Funded through the company that built this tool.

RRE Ventures
VC T1
New York, United States
$5M-$25M
RRE Ventures is a New York-based early-stage firm founded in 1994 by Stuart Ellman and Jim Robinson IV, with a portfolio that…
AI/ML in Healthcare Care Delivery / Tech-Enabled Services
AI Tool Finder
AI-powered search. Results may not be comprehensive.